In a phase II single-arm study, 24 chemorefractory MMRp metastatic CRC patients received durvalumab (anti-PD-L1), tremelimumab (anti-CTLA-4), and radiotherapy. This evidence concerns the gene CTLA4 and colorectal carcinoma.